Structure Based Drug Design

The three-dimensional structure of a target protein, especially with bound ligand, is a valuable source of information to guide drug discovery. A number of structure-based drug design tools, complemented by ligand-based approaches, can be used for the design and Optimization of new compounds.

Structure Based Drug Design

  • Sygnature’s close collaboration with Peak Proteins allows us to generate protein constructs and obtain X-ray crystallography data on behalf of customers for targets lacking structural information and to elucidate the binding mode of representative leads to drive structure-based optimisation.
  • We have extensive experience in generating homology models based on related proteins for any targets that lack structural data and prove difficult to crystallize.
  • Our expert computational team analyses all available structural information and shares results and 3D visualization tools with the medicinal chemistry teams to encourage idea generation and improve compound design.
  • Flexible ligand docking and 4D docking, to account for protein flexibility, are applied to prioritize design ideas and a 3D fully-interactive ligand editor can be used for ligand optimization in the binding site.
  • A range of modern techniques are used to assess and rank the affinity and stability of binding poses, including short trajectory MD simulations, MM/PBSA and Grid Free Energy calculations.
  • We can apply water assessment technology to identify favourable and unfavourable regions of solvent thermodynamics in the binding site. Introduction of polar functionalities to a lead compound, based on this understanding of the water structure, can often benefit physical properties as well as potency and specificity.

We are passionate about acquiring and using cutting-edge tools to advance drug discovery and are always looking for ways to improve our capabilities. We have therfore initiated a collaboration with a leading academic expert in Free Energy Perturbation (FEP) calculations. As part of this ongoing effort, we are investigating the factors affecting the accuracy of protein-ligand binding free energy estimates. In a recent study, we highlighted the impact of the initial crystal structure on the resulting free energy predictions and emphasized the importance of rare event sampling and long-timescale dynamics when running FEPs. We are currently working on finding computational solutions to improve the prediction accuracy.

Latest News

View All

Sygnature Discovery and UBE Corporation successfully identify…

Five Arrows invests in Sygnature Discovery

Sygnature Discovery’s Early CMC Development Expansion: Unveiling…

Sygnature Discovery expands US presence with Bay…